Chatelain, Pierre,
Malievskiy, Oleg,
Radziuk, Klaudziya,
Senatorova, Ganna,
Abdou, Magdy O.,
Vlachopapadopoulou, Elpis,
Skorodok, Yulia,
Peterkova, Valentina,
Leff, Jonathan A.,
Beckert, Michael (2017) Context: TransCon Growth Hormone (GH) (Ascendis Pharma) is a
long-acting recombinant sustained
Дьяконов, В.А.,
Джемилева, Л.У.,
Джемилев, У.М.,
D'yakonov, V.A.,
Dzhemileva, L.U.,
Dzhemilev, U.M. (2017) that would
act on molecular targets, the targets that play an important role in carcinogenesis.
Numerous
Tseylikman, V.E.,
Davydovich, M.G.,
Tseilikman, O.B.,
Feklicheva, I.V.,
Shankova, N.A.,
Boyarinova, N.V. (2017) by
Act 211 Government of the Russian Federation, contract № 02.A03.21.0011 and by financial support
Motloch, L.J.,
Larbig, R.,
Darabi, T.,
Reda, S.,
Motloch, K.A.,
Wernly, B.,
Lichtenauer, M.,
Gebing, T.,
Schwaiger, A.,
Zagidullin, N.,
Wolny, M.,
Hoppe, U.C. (2017) Background Caveolin-3 (cav-3) mutations are linked to the
long-QT syndrome (LQTS) causing distinct